CB-839: Updated Ph I data

Updated data from a cohort of 15 evaluable patients with renal cell carcinoma (RCC) in the open-label, dose-escalation, U.S. Phase I CX-839-001 trial showed that 400-800 mg CB-839 twice daily plus 10 ...